Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaji, R.
Right arrow Articles by Sumner, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaji, R.
Right arrow Articles by Sumner, A. J.
NEUROLOGY 1988;38:1884
© 1988 American Academy of Neurology

Effects of 4-aminopyridine in experimental CNS demyelination

Ryuji Kaji, MD, PhD and Austin J. Sumner, MD

Department of Neurology, University of Pennsylvania, Philadelphia, PA.

We studied the effect of systemically administered 4-aminopyridine in a model of CNS demyelination. In five rats with demyelination, slowed conduction velocity through the lesion was partially reversed at dose levels of 5.6 to 7.2 mg/kg. All rats developed convulsion at this dosage, and impaired conduction of high-frequency impulses was unchanged. These findings suggest certain limitations of 4-aminopyridine as a therapeutic agent.

Address correspondence and reprint requests to Dr. Kaji, Department of Neurology, Louisiana State University Medical Center, 1542 Tulane Avenue, New Orleans, LA 70124.

Presented in part at the thirty-ninth annual meeting of the American Academy of Neurology, New York, NY, April 1987.

Received April 21, 1988. Accepted for publication in final form June 29, 1988.




This article has been cited by other articles:


Home page
 NeurologyHome page
A. D. Goodman, T. R. Brown, J. A. Cohen, L. B. Krupp, R. Schapiro, S. R. Schwid, R. Cohen, L. N. Marinucci, A. R. Blight, and For the Fampridine MS-F202 Study Group
Dose comparison trial of sustained-release fampridine in multiple sclerosis
Neurology, October 7, 2008; 71(15): 1134 - 1141.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. Q. Wang, A. Y. Xiao, A. Yang, L. LaRose, L. Wei, and S. P. Yu
Block of Na+,K+-ATPase and Induction of Hybrid Death by 4-Aminopyridine in Cultured Cortical Neurons
J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 502 - 506.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
K. J. Smith, P. A. Felts, and G. R. John
Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension
Brain, January 1, 2000; 123(1): 171 - 184.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.